Scientific publications by IMI
-
Nature Microbiology, Vol. 6, p. 137, published online 28 January 2021
Meulien, P. (2021) Innovative Medicines Initiative plays the long game on research funding -
European Psychiatry, Vol. 50, pp. 57-59
Vaudano, E. (2018) Public–private partnerships as enablers of progress in the fight against mental disorders: The example of the European Innovative Medicines Initiative -
The Lancet, Vol. 388, p. 865
Matthiessen, L. et al. (2016) Increased momentum in antimicrobial resistance research -
Nature Biotechnology, Vol. 33, pp. 811–812 (2015), published online 7 August 2015
Gunn, M., Lim, M., Cross, D. & Goldman, M. (2015) Benchmarking the scientific output of the Innovative Medicines Initiative -
Nature Reviews Drug Discovery, published online 12 December 2014
Goldman, M., Seigneuret, N. & Eichler, H.-G. (2014) The Innovative Medicines Initiative: an engine for regulatory science -
Journal of Health Policy and Outcomes Research, Vol. 2, pp. 12-17
Wittelsberger, A. & Goldman, M. (2014) Public-private collaboration to advance the development and benefit-risk assessment of vaccines: The Innovative Medicines Initiative -
New England Journal of Medicine, Vol. 370, pp. 2163-2165
Kush, R. & Goldman, M. (2014) Fostering responsible data sharing through standards -
Nature Reviews Drug Discovery , Vol.13, pp. 239–240
Marti-Solano, M., Birney, E., Bril, A. , Della Pasqua, O., Kitano, H., Mons, B., Xenarios, I. & Sanz, F. (2014) Integrative knowledge management to enhance pharmaceutical R&D -
Marquette Intellectual Property Law Review, Vol. 18 (1), pp. 31-32
Laverty, H. & Poinot, P. (2014) IP policy forum: Intellectual property rights (IPR) in collaborative drug development in the EU: Helping a European public-private partnership deliver - the need for a flexible approach to IPR -
Computational and Structural Biotechnology Journal, Vol. 6 (7), e201303017
Vaudano, E. (2013) The Innovative Medicines Initiative: a public private partnership model to foster drug discovery -
Alternatives to Laboratory Animals (ATLA), Vol. 40 (6), pp. 307-312
Gunn, M. et al. (2013) The rational use of animals in drug development: contribution of the innovative medicines initiative -
European Journal of Immunology, Vol. 43 (2), pp. 298-302
Goldman, M. et al. (2013) The Innovative Medicines Initiative moves translational immunology forward -
Clinical and Translational Medicine, Vol. 2 (2), published online 15 January 2013
Goldman, M. et al. (2013) Public-private partnerships as driving forces in the quest for innovative medicines -
Expert Review of Pharmoeconomics & Outcomes research, Vol.12 (5), pp. 545-548
Laverty, H. et al. (2012) Improving R&D productivity of pharmaceutical companies through public-private partnership: experiences from the Innovative Medicines Initiative -
Nature Reviews Drug Discovery, published online 30 March 2012
Denee, T.R. et al. (2012) Measuring the value of public–private partnerships in the pharmaceutical sciences -
Nature Medicine, Vol. 18, p. 341
Goldman, M. (2012) Public-private partnerships need honest brokering -
Clinical Pharmacology and Therapeutics, Vol. 91 (3), pp. 418-125
Goldman, M. (2012) The Innovative Medicines Initiative: A European Response to the Innovation Challenge -
Nature Biotechnology, Vol. 29, pp. 689–690
Strohmeier, R. et al. (2011) IMI moves forward -
Nature Reviews Drug Discovery, Vol. 10, pp. 321-322
Goldman, M. (2011) Reflections on the Innovative Medicines Initiative -
Nature, Vol. 466, pp. 1040-1041
Goldman, M. and De Rijck, K. (2010) Opinion: Clarifying knowledge ownership in Europe’s medicines initiative